ASH 2007
Date: December 8-11, 2007
Loacation: Atlanta, Georgia
Thrombopoietin Receptor Agonists & Immune Thrombocytopenic Purpura (ITP): A Report from the 2007 American Society of Hematology (ASH) Meeting
Charles S. Abrams, MD, Associate Professor of Medicine, Director, Thrombophilia Program, University of Pennsylvania Health System, Philadelphia, Pennsylvania
Advances in the Management of Chronic Myeloid Leukemia: A Report from the 2007 American Society of Hematology (ASH) Meeting
Hagop M. Kantarjian, MD, Chairman & Professor, Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting
Mikkael A. Sekeres, MD, MS, Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
Tibsovo Treatment of Acute Myeloid Leukemia
Tibsovo approved for treatment of newly diagnosed and relapsed Acute Myeloid Leukemia with an IGH1 mutation
Bispecific Antibody Precision Immunotherapy in non-Hodgkin lymphoma
Epcoritimab and other bi-specific antibody immunotherapies effective in refractory NHL - New option for elderly patients?
Male BRCA2 Carriers Have Increased Lifetime Risk of Breast Cancer
Some men are at increased hereditary risk of developing breast cancer.
Supportive Care and Hematologic Malignancies: Updates from the 2007 American Society of Hematology (ASH) Meeting
C. Dean Buckner, MD, Founding Member, Fred Hutchinson Cancer Research Center
